asymmetric dimethylarginine

Asymmetric dimethylarginine [an endogenous inhibitor of nitric oxide synthase (NOS)], is a compound that inhibits the enzyme responsible for producing nitric oxide.

Asymmetric dimethylarginine (Standard) is a reference standard for research and analysis in studies involving Asymmetric dimethylarginine. Asymmetric dimethylarginine is an endogenous inhibitor of nitric oxide synthase (NOS)

Ibulocydine is a potent CDK inhibitor. Ibulocydine has high activity against Cdk7/cyclin H/Mat1 and Cdk9/cyclin T. Ibulocydine inhibited the growth of HCC cells more effectively than other Cdk inhibitors, including olomoucine and roscovitine, whereas ibulocydine as well as the other Cdk inhibitors and BMK-Y101 minimally influenced the growth of normal hepatocyte cells. Ibulocydine induced apoptosis in HCC cells, most likely by inhibiting Cdk7 and Cdk9. In vitro treatment of HCC cells with ibulocydine rapidly blocked phosphorylation of the carboxyl-terminal domain (CTD) of the large subunit of RNA polymerase II, a process mediated by Cdk7/9. Anti-apoptotic gene products such as Mcl-1, survivin, and X-linked IAP (XIAP) are crucial for the survival of many cell types, including HCC. Following the inhibition of RNA polymerase II phosphorylation, ibulocydine caused rapid down-regulation of Mcl-1, survivin, and XIAP, thus inducing apoptosis. Furthermore, ibulocydine effectively ind......

Adma-D6 (Standard) is a reference standard of Adma-D6 intended for quantitative analysis, quality control, and related biochemical research applications. NG,NG-dimethyl-L-arginine-d6 (ADMA-d6) (hydrochloride) is used as an internal standard when quantitatively analyzing NG,NG-dimethyl-L-arginine by gas chromatography-mass spectrometry or liquid chromatography-mass spectrometry. NG,NG-dimethyl-L-arginine is an endogenous inhibitor of nitric oxide synthase (NOS).

PRMT1-IN-3 is a potent inhibitor of protein arginine methyltransferase 1 (PRMT1) with an IC50 of 4.11 μM. It also inhibits PRMT6 and PRMT8, with IC50 values of 23.3 and 30.1 μM, respectively. In triple-negative breast cancer (TNBC) cells, PRMT1-IN-3 reduces asymmetric dimethylarginine (ADMA) levels and the histone modification H4R3me2a. It induces cell cycle arrest and apoptosis in MDA-MB-231 cells and inhibits cell migration and colony formation. Furthermore, PRMT1-IN-3 serves as a chemosensitizer for Paclitaxel and is applicable in TNBC research.

SKLB06329 is a potent and selective inhibitor of type I PRMTs. It demonstrates strong selectivity for PRMT6 (IC50= 3.86 nM) without significantly inhibiting type II/III PRMTs (such as PRMT5/7) or various protein lysine methyltransferases [PKMTs]. SKLB06329 effectively suppresses the proliferation of triple-negative breast cancer [TNBC] cells, induces apoptosis, and inhibits the expression of asymmetric dimethylarginine [ADMA] within cells. This compound is applicable for research related to triple-negative breast cancer.